BLAINJECTIONINJECTABLE
Approved
Sep 2024
Lifecycle
Growth
Competitive Pressure
30/100
Clinical Trials
3
Data completeness
4/8 — Partial
EBGLYSS (lebrikizumab-lbkz) by Eli Lilly and Company is interleukin-13 antagonists [moa]. Approved for interleukin-13 antagonist [epc]. First approved in 2024.
Drug data last refreshed 1h ago · AI intelligence enriched 1w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
EBGLYSS (lebrikizumab-lbkz) is a monoclonal antibody that antagonizes interleukin-13, a key cytokine driver of type 2 inflammation. Approved by the FDA on September 13, 2024, it targets IL-13-mediated diseases. The drug is administered via injection and represents a novel mechanism for treating IL-13-driven conditions.
Growth
Early-stage product in growth phase with commercial infrastructure ramping; expect expanding field and marketing team size over next 2-3 years.
Mechanism of Action
Interleukin-13 Antagonists
Pharmacologic Class:
Interleukin-13 Antagonist
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Clinical Trials (3)
A Study of (LY3650150) Lebrikizumab to Assess the Safety and Efficacy of Adult and Adolescent Participants With Moderate-to-Severe Atopic Dermatitis and Skin of Color
Started Jan 2023
90 enrolled
Atopic Dermatitis
Long-term Safety and Efficacy Study of Lebrikizumab (LY3650150) in Participants With Moderate-to-Severe Atopic Dermatitis (ADjoin)
Started Jun 2020
1,153 enrolled
Atopic Dermatitis
Study to Assess the Safety and Efficacy of Lebrikizumab (LY3650150) in Adolescent Participants With Moderate-to-Severe Atopic Dermatitis
Started Feb 2020
206 enrolled
Atopic Dermatitis
Career Relevance
Worked on EBGLYSS at Eli Lilly and Company? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.